Full-Time

Director of Pharmacovigilance and Drug Safety Operations

Remote

Posted on 10/18/2024

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Biotechnology
Healthcare

Expert

New York, NY, USA

Hybrid role with potential in-office requirements.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • RN, MS, MPH, PharmD or equivalent degree
  • Minimum 15 years of drug development experience in the pharmaceutical industry
  • Must have experience in phase 1 early stage programs through phase 3 late stage programs
  • Must have experience in global clinical studies and reporting requirements
  • Strong understanding of PV processes and quality requirements
  • Experience with ArisGlobal LSMV and Veeva Vault systems is preferred
  • Must be able to command respect from peers and capable of highly independent work as well as being a team player and role model
  • Must be a highly motivated, decisive, and results-oriented individual with the flexibility and creativity to excel in and contribute to a rapidly growing company
  • Requires proven ability to manage multiple projects.
Responsibilities
  • Works with external vendors on safety case processing and systems management
  • Develops and implements when necessary drug safety/PV infrastructure and systems
  • Oversees and manages Roivant’s safety database system
  • Oversees safety processes and SOPs
  • Works with existing drug safety team at Roivant and at subsidiary Vants to insure all drug safety responsibilities are appropriately handled
  • Works closely with regulatory affairs at Roivant and/or at the subsidiary Vants to insure all drug safety regulatory reporting requirements are met
  • Responsible for developing and managing any pharmacovigilance agreements with external partners
  • Be able to assess clinical study specific safety, whether it is at the study design standpoint or at the level of a specific safety case report
  • Handle in-licensing due diligence from a drug safety/PV standpoint
  • Functions as the drug safety/pharmacovigilance subject matter expert on program and diligence teams
  • Keeps up to date on changing regulatory landscape as it applies to drug safety and pharmacovigilance

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant employs a unique business model that combines in-house development with strategic partnerships, allowing it to build a diverse pipeline of drug candidates. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

New York City, New York

Founded

2014

Growth & Insights
Headcount

6 month growth

1%

1 year growth

1%

2 year growth

-1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.
  • Strategic partnerships with Bayer and Roche accelerate drug development and market entry.
  • Increased investment from financial institutions highlights confidence in Roivant's growth potential.

What critics are saying

  • Integration challenges from Dermavant acquisition may disrupt operations and delay development.
  • Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.
  • Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

What makes Roivant Sciences unique

  • Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.
  • The company builds Vants, nimble biotech firms, to enhance drug development efficiency.
  • Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE